- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J3590
    - J1745
    - J0135
  conditions:
    all_of:
    - dx_in_value_set: vs_crohns_disease_2025_09
    - has_flag: moderate_severe_disease
    - has_flag: conventional_therapy_failed
    - has_flag: tb_screening_negative
    none_of:
    - dx_in_value_set: vs_active_infection_2025_09
    - dx_in_value_set: vs_malignancy_active_2025_09
    - has_flag: live_vaccine_recent
  logic:
    outcome: PA_REQUIRED
    notes: IBD biologic therapy requires moderate-severe disease with failed conventional
      therapy and negative TB screening
  precedence: 95
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_ibd_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_dd03f6d0c0d9
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J3590
  conditions:
    all_of:
    - dx_in_value_set: vs_crohns_disease_2025_09
    - has_flag: anti_tnf_failure
    - has_flag: moderate_severe_disease
    none_of:
    - dx_in_value_set: vs_active_infection_2025_09
    - has_flag: malignancy_history_5_years
  logic:
    outcome: PA_REQUIRED
    notes: Ustekinumab biologic for Crohn's disease requires anti-TNF failure with
      moderate-severe disease
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_ibd_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_9d773b61e350
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - '45378'
    - '43239'
  conditions:
    any_of:
    - all_of:
      - dx_in_value_set: vs_ulcerative_colitis_2025_09
      - has_flag: disease_duration_8_years_plus
    - all_of:
      - dx_in_value_set: vs_crohns_colitis_2025_09
      - has_flag: disease_duration_8_years_plus
    - dx_in_value_set: vs_primary_sclerosing_cholangitis_2025_09
    none_of:
    - has_flag: surveillance_colonoscopy_within_2_years
  logic:
    outcome: PA_REQUIRED
    notes: IBD surveillance colonoscopy screening every 1-2 years after 8 years of
      disease duration
  precedence: 85
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_ibd_surveillance_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_2c026bff7dd3
- type: EDIT
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J3590
    - J1745
  conditions:
    all_of:
    - dx_in_value_set: vs_ibd_mild_2025_09
    none_of:
    - has_flag: steroid_dependent
    - has_flag: perianal_disease
    - has_flag: extraintestinal_manifestations
  logic:
    outcome: DENY
    notes: Biologic therapy for mild IBD requires steroid dependence, perianal disease,
      or extraintestinal manifestations
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_ibd_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_6f3a1ac03da3
